Insmed’s New Lung Disease Study Data A Win For Company, Says Analyst

• Truist has a ‘Buy’ rating on the shares with a price target of $205, representing a potential upside of about 51% from Friday’s closing price.
• Truist’s current base assumption is that Arikayce sales growth rate will remain stable though it needs to better understand the impact of a label expansion, the firm said.

Insmed (INSM) on Monday announced positive results from its trial studying its drug Arikayce in combination with other drugs in patients with a new occurrence of Mycobacterium avium complex (MAC) lung infection. The announcement garnered appreciation on Wall Street.

Truist analyst Danielle Brill said the firm believes the trial data for Arikayce is sufficient for both conversion to full approval for refractory MAC and full approval for all MAC lung disease.

Truist’s current base assumption is that Arikayce sales growth rate will remain stable though it needs to better understand the impact of a label expansion, the firm said. The firm views the successful study readout as a win for Insmed, especially considering any acceleration in Arikayce sales growth represents upside to its model.

Truist has a ‘Buy’ rating on the shares with a price target of $205, representing a potential upside of about 51% from Friday’s closing price. INSM shares traded up 6% at the time of writing.  

About Arikayce And Trial

Arikayce currently has limited FDA-approval in combination with multidrug therapy for adults with refractory MAC lung disease but more study was required for a full traditional approval in the indication. With the fresh study, Insmed seeks to file for a full approval of the drug in the indication. 

Insmed also plans to file a supplemental new drug application for Arikayce in patients with all MAC lung disease in the second half of 2026 based on the trial.

In the recent trial, Insmed was studying Arikayce plus azithromycin and ethambutol versus placebo plus multidrug therapy once-daily in diagnosed patients with a new occurrence of MAC lung infection who had not received antibiotics. The study met primary endpoints, demonstrating statistically significant and clinically meaningful improvements in respiratory symptom score and culture conversion rates. Further, no new safety signals were observed, the company said.

Mycobacterium avium complex (MAC) lung disease is a chronic, non-contagious infection caused by bacteria found in soil and water. It frequently causes fatigue, cough, and weight loss.

How Did Stocktwits Users React?

On Stocktwits, retail sentiment around INSM stock jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.

INSM stock has gained 81% over the past 12 months. 

Read More: Tesla’s Service Raises Concerns In Wall Street Even As Upcoming Semi Truck Garners Interest

For updates and corrections, email newsroom[at]stocktwits[dot]com.